“Within just six months of our initial Series A funding, Attenua has successfully filed an Investigational New Drug (IND) application, received Institutional Review Board (IRB) approval at 17 clinical trial sites, manufactured drug and launched a Phase 2 clinical trial with bradanicline in chronic cough,” said Michael Kitt, M.D., Chief Executive Officer of Attenua. “This is a testament to our experienced team and focused execution at top-tier clinical trial sites.”
The Phase 2 randomized, double-blind, dose-escalation, crossover study will test the efficacy and safety of bradanicline in up to 49 patients with refractory chronic cough. Refractory chronic cough is defined as a cough that persists for eight weeks or more. Patients will receive daily either escalating doses of drug or matching placebo for three weeks, followed by a 14-day washout period, before crossing over to the opposite treatment for three weeks. Cough frequency will be assessed with an objective cough recording device every seven days. For more information, please visit www.clinicaltrials.gov.
“We look forward to testing bradanicline in this proof-of-concept study, which focuses on a new mechanism of action that is believed to play a key role in chronic cough,” said principal investigator Jacky Smith, MD, Professor of Respiratory Medicine at the University of Manchester, UK.
Attenua plans to conduct additional clinical trials to test the safety and efficacy of bradanicline in 2019.
Lianyungang Klinechem Co., Ltd
Contact Person: Dr. John Liu
Address: Jingqi Road, Weiwu Road, Coastal Industrial Park, Guanyun County, Lianyungang City, Jiangsu Province